Table 2.
Correlation between ELABELA and study variables in all subjects
| r | P value | |
|---|---|---|
| Age, years | − 0.300 | < 0.001*** |
| Male sex | 0.007 | 0.932 |
| Body mass index, kg/m2 | 0.158 | 0.074 |
| Coronary heart disease | 0.007 | 0.926 |
| Diabetes Mellitus | − 0.016 | 0.840 |
| Hyperlipidemia | 0.107 | 0.174 |
| Systolic blood pressure, mmHg | 0.122 | 0.121 |
| Diastolic blood pressure, mmHg | − 0.010 | 0.900 |
| Mean arterial pressure, mmHg | 0.052 | 0.513 |
| Heart rate, bpm | − 0.156 | 0.047* |
| BNP, pg/ml | − 0.330 | < 0.001*** |
| Creatine, umol/l | − 0.134 | 0.110 |
| Hemoglobin A1C, % | − 0.040 | 0.648 |
| LDL-c, mmol/l | 0.076 | 0.369 |
| HDL-c, mmo/l | 0.084 | 0.327 |
| Total cholesterol, mmol/l | 0.130 | 0.125 |
| Homocysteine, umol/l | − 0.134 | 0.113 |
| ESR, mm/h | − 0.073 | 0.417 |
| Hs-CRP, mg/l | − 0.152 | 0.100 |
| Troponin I, ng/ml | − 0.010 | 0.908 |
| LAD, mm | − 0.289 | 0.001** |
| LVEDd, mm | 0.003 | 0.976 |
| LVEDs, mm | − 0.089 | 0.326 |
| LVEF, mm | 0.117 | 0.195 |
| ACEI or ARB | 0.096 | 0.223 |
| Beta blocker | 0.052 | 0.512 |
| CCBs | − 0.046 | 0.560 |
| Diuretics | − 0.068 | 0.390 |
BNP brain natriuretic peptide, LDL-c low density lipoprotein cholesterol, HDL-c high density lipoprotein cholesterol, ESR erythrocyte sedimentation rate, hs-CRP high-sensitivity C-reactive protein, LAD left atrial diameter, LVEDd left ventricular end diastolic diameter, LVEDs left ventricular end systolic diameter, LVEF left ventricular ejection fraction, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor antagonists, CCBs Calcium channel blockers
*P value less than 0.05; **P value less than 0.01; ***P value less than 0.001